Status:
COMPLETED
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This 2 arm study will investigate Quality of Life response in anemic participants with solid and lymphoid malignancies, who are receiving concomitant chemotherapy. Participants with solid and lymphoid...
Eligibility Criteria
Inclusion
- Anemia and prescribed treatment with epoetin beta
- Confirmed diagnosis of a solid or lymphoid hematologic malignancy
- Receiving or scheduled to receive chemotherapy
- Life expectancy of greater than or equal to (\>=6) months
Exclusion
- Anemia after bleeding, hemolytic anemia, megaloblastic anemia, anemia in chronic kidney failure, lever and endocrinology diseases
- Contraindications to epoetin beta
- Administration of epoetin beta during chemotherapy (e.g., on the third day after chemotherapy cycle start)
- Bleeding within one month before and/or during study
- Severe infection within one month before and/or during study
- Inability of participant to fill the questionnaires
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT00776425
Start Date
January 1 2007
End Date
November 1 2012
Last Update
July 2 2017
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkhangelsk, Russia, 163061
2
Barnaul, Russia, 656049
3
Belgorod, Russia, ND
4
Ivanovo, Russia, 153040